Thane Wettig
Chief Executive Officer at FIBROGEN, INC.
Net worth: 458 547 $ as of 2024-04-29
Thane Wettig active positions
| Companies | Position | Start | End |
|---|---|---|---|
| FIBROGEN, INC. | Director/Board Member | 2023-10-01 | - |
| Chief Executive Officer | 2023-07-22 | - | |
| Corporate Officer/Principal | 2020-06-21 | 2023-07-22 |
Career history of Thane Wettig
Former positions of Thane Wettig
| Companies | Position | Start | End |
|---|---|---|---|
| Lilly Diabetes | Corporate Officer/Principal | 1989-12-31 | 2008-12-31 |
| Sales & Marketing | 2008-12-31 | - | |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | 2017-12-31 | - |
Training of Thane Wettig
| Washington University in St. Louis | Masters Business Admin |
Statistics
International
| United States | 5 |
Operational
| Corporate Officer/Principal | 3 |
| Masters Business Admin | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Lilly Diabetes |
- Stock Market
- Insiders
- Thane Wettig
- Experience